Nyrada

16 February 2021

Sydney, Australia

## **Cleansing Statement**

**Sydney, 16 February 2021**: Nyrada Inc (ASX: NYR), issued further to the Appendix 2A lodged on 16 February 2021:

• 1,355,000 CHESS Depositary Interests (CDIs) from the exercise of 1,355,000 Scientific Advisory Board options (ASX: NYRAI).

NYR gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

- 1 The CDIs were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
- 2 As at the date of this notice, NYR has complied with:
  - (a) The provisions of Chapter 2M of the Corporations Act as they apply to NYR; and
  - (b) Section 674 of the Corporations Act.
- 3 As at the date of this notice, there is no information that is "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under section 708A(6)(e) of the Corporations Act.

For and on behalf of the Board,

Yours faithfully,

David Franks

**Company Secretary** 

## About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

## www.nyrada.com

Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.



Investor & Corporate Enquiries: Laura Vize Investor Relations Manager T: 0417 026 056 E: <u>info@nyrada.com</u> Company Secretary: David Franks T: 02 8072 1400 E: David.Franks@automicgroup.com.au

Media Enquiries: Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: <u>cstrong@citadelmagnus.com</u>

## Forward-Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.